Walsopan-D Capsule PR is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Pantoprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The combination of these agents offers a synergistic approach by addressing both delayed gastric emptying and excessive gastric acid production. Walsopan-D Capsule PR is indicated for the treatment of acid peptic disorders accompanied by motility disturbances, such as functional dyspepsia and GERD with associated nausea and vomiting. It should be administered as per physician’s guidance, considering patient-specific factors and contraindications. Caution is advised in patients with underlying cardiac conditions due to Domperidone’s potential to prolong the QT interval. Common side effects may include headache, dry mouth, and abdominal cramps. This medication should be used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.